News|Articles|November 4, 2025

Join Us Tonight: Inside Trump’s Drug Price Plan

Listen
0:00 / 0:00

Key Takeaways

  • The webinar will examine MFN's effects on acquisition costs, reimbursement, and prescribing workflows.
  • Discussion will include the impact of DTC distribution on prior authorizations and patient counseling.
SHOW MORE

Part three of our three-part webinar series airs live tonight at 7 p.m. ET, unpacking how most favored nation pricing, import tariffs and direct-to-consumer channels could ripple through payer contracts, 340B and practice economics.

The final session of Pharmaceutical Executive’s and MJH Life Sciences’ three-part webinar series on President Trump’s “Most Favored Nation” (MFN) drug-pricing is tonight, Nov. 4 at 7 p.m. ET.

Register here for “Most Favored Nation Order: How Trump Is Disrupting Pharma: Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets.”

The webinar looks at how MFN could be operationalized alongside emerging DTC channels and potential tariffs — and what those moving parts mean in day-to-day terms:

Questions we'll answer:

  • What would an MFN style benchmark do to acquisition costs and reimbursement mechanics?
  • Where could mandatory payment models like GLOBE and GUARD fit, and how might they change prescribing and purchasing workflows?
  • How could a shift toward DTC distribution affect prior authorizations, cash pay conversations and patient counseling at the point of care?
  • What would this mean for 340B participants, specialty-drug flows and buy-and-bill margins?

Meet the panel

  • Moderator: Ronald W. Lanton III, Esq. — Partner at Lanton Law, Lanton has spent more than 25 years working at the intersection of health care law and government affairs at the municipal, state and federal levels.
  • Neal Masia, Ph.D. — Co‑founder and CEO of EntityRisk; founder of Health Capital Group; adjunct professor of management and economics at Columbia University. Masia brings a market-access lens from years in biopharma leadership.
  • Stacie B. Dusetzina, Ph.D. — Professor of health policy and Ingram professor of Cancer Research at Vanderbilt University School of Medicine. Dusetzina focuses on how policy and pricing shape patient access.
  • Lindsay Greenleaf, J.D., MBA — Head of policy, research and analysis at ADVI Health. Greenleaf translates legislation and regulation into commercialization and access strategies across pharma, devices, diagnostics and physician practices.

Catch up on parts one and two

Missed the first two sessions? Stream the full recordings and find key takeaways:

  1. Part 1: Register and watch here.
  2. Part 2: Register and watch here.

How to join

Date and Time: Tonight at 7:00 p.m. ET

Topic: Most Favored Nation Order: How Trump Is Disrupting Pharma: Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets

Register: Click here to reserve your seat now!

This series is produced by MJH Life Sciences® in collaboration with The American Journal of Managed Care®, Chief Healthcare Executive®, Drug Topics®, HCPLive®, Managed Healthcare Executive®, Medical Economics®, OncLive®, Pharmaceutical Commerce®, Pharmaceutical Executive®, and Pharmacy Times®.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.